{"url_path":"/sec/slno/8-k/2026-05-18/item-5-01","section_key":"item-5-01","section_title":"Item 5.01 Changes in Control of Registrant","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","accession_number":"0001193125-26-228016","cik":"0001484565","ticker":"SLNO","issuer_name":"SOLENO THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","primary_entity_key":"0001484565","primary_entity_name":"SOLENO THERAPEUTICS INC"},"word_count":73,"has_tables":true,"body_markdown":"Item 5.01.\n\nChanges in Control of Registrant\n\nAs a result of the completion of the Merger, a change in control of the Company occurred, and the Company became a direct wholly owned subsidiary of Parent. The Offer Consideration was funded through Parent’s cash on hand.\n\nThe information set forth in the Introductory Note and Items 2.01 and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01."}